PNC Financial Services Group
CHRS icon

PNC Financial Services Group’s Coherus Oncology CHRS Stock Holding History

PNC Financial Services Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-327
Closed -$264 – 4942
2025
Q1 		$264 Buy
327
+229
+234% +$264 ﹤0.01% 4742
2024
Q4 		$135 Hold
98
– – ﹤0.01% 4692
2024
Q3 		$102 Sell
98
-176
-64% -$241 ﹤0.01% 4723
2024
Q2 		$474 Sell
274
-408
-60% -$821 ﹤0.01% 4542
2024
Q1 		$1.63K Buy
682
+128
+23% +$315 ﹤0.01% 4254
2023
Q4 		$1.84K Sell
554
-4,003
-88% -$10.7K ﹤0.01% 4210
2023
Q3 		$17K Buy
4,557
+2,318
+104% +$10.7K ﹤0.01% 3505
2023
Q2 		$9.56K Sell
2,239
-1,469
-40% -$8.67K ﹤0.01% 3892
2023
Q1 		$25.4K Sell
3,708
-5,722
-61% -$44.4K ﹤0.01% 3381
2022
Q4 		$74.7K Sell
9,430
-127
-1% -$977 ﹤0.01% 2750
2022
Q3 		$91K Sell
9,557
-2,801
-23% -$28.3K ﹤0.01% 2595
2022
Q2 		$88K Buy
12,358
+6,245
+102% +$54.3K ﹤0.01% 2659
2022
Q1 		$79K Sell
6,113
-2,016
-25% -$25.6K ﹤0.01% 2843
2021
Q4 		$129K Buy
8,129
+3,614
+80% +$63.2K ﹤0.01% 2519
2021
Q3 		$72K Buy
4,515
+1,367
+43% +$20K ﹤0.01% 2838
2021
Q2 		$44K Buy
3,148
+969
+44% +$13.7K ﹤0.01% 3134
2021
Q1 		$32K Buy
2,179
+247
+13% +$4.19K ﹤0.01% 3207
2020
Q4 		$34K Sell
1,932
-609
-24% -$10.8K ﹤0.01% 3113
2020
Q3 		$47K Buy
2,541
+733
+41% +$13.6K ﹤0.01% 2771
2020
Q2 		$34K Buy
1,808
+444
+33% +$7.51K ﹤0.01% 2968
2020
Q1 		$22K Sell
1,364
-70
-5% -$1.29K ﹤0.01% 3057
2019
Q4 		$26K Sell
1,434
-68,152
-98% -$1.26M ﹤0.01% 3210
2019
Q3 		$1.41M Sell
69,586
-27,668
-28% -$553K ﹤0.01% 1121
2019
Q2 		$2.15M Buy
+97,254
New +$1.69M ﹤0.01% 986
2015
Q1 		– Sell
-7,580
Closed -$124K – 4698
2014
Q4 		$124K Buy
+7,580
New +$107K ﹤0.01% 2352

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

PNC Financial Services Group's CHRS Position: Q2 2025 in Review

PNC Financial Services Group sold out of Coherus Oncology (CHRS) in Q2 2025, closing a stake of 327 shares — an estimated $264 sold.

PNC Financial Services Group first reported a position in CHRS in Q4 2014 and held it in 25 quarters. The position peaked at $2.15M in Q2 2019. 112 funds tracked by Wall St. Rank hold CHRS as of Q2 2025.

  • PNC Financial Services Group reported no remaining Coherus Oncology position as of Q2 2025 after selling out during the quarter.
  • PNC Financial Services Group sold 327 Coherus Oncology shares in Q2 2025, an estimated $264.
  • PNC Financial Services Group first reported a position in Coherus Oncology in Q4 2014 and held it in 25 quarters.
  • PNC Financial Services Group's Coherus Oncology position peaked at $2.15M in Q2 2019.
  • 112 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2025.

Based on PNC Financial Services Group's 13F filing for Q2 2025, filed 8 Aug 2025.